Viridian Therapeutics presents VRDN-008 Phase 1 data showing 74% peak IgG reduction
VRDN•Viridian Therapeutics said Phase 1 data for VRDN-008 showed a peak IgG reduction of 74%, sustained through eight weeks after dosing. The company plans to start a registrational myasthenia gravis trial in mid-2027.
1. Phase 1 findings
In healthy volunteers, VRDN-008 showed a peak IgG reduction of 74%, with reductions sustained through eight weeks following dosing. The drug had a half-life of 15-18 days and was generally well tolerated, with no serious adverse events or dose-limiting toxicities.
2. Planned trial
Viridian plans to initiate a registrational trial of subcutaneous VRDN-008 in myasthenia gravis in mid-2027. The trial will compare dosing every eight weeks, dosing every four weeks and placebo, using MG-ADL as the primary endpoint.
